ClinicalTrials.govpublic full text
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
neoplasms, breast, erbb2 overexpressing, erbb2 positive, lapatinib, invasive breast cancer, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 915934
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.